Related to Daiichi Sankyo Becomes First Firm to License BioWa and Lonza’s Fucose-Free mAb Cell Line

• Daiichi and BioInvent Team Up in Antibody Therapeutics Collaboration
  
• Ehrfeld Mikrotechnik Nabs Worldwide Manufacturing and Distribution License to Lonza’s Microreactors
  
• Lonza Enters Pluripotent Stem Cell Market through Distribution Arrangement for Axiogenesis’ Cardiomyocyte Products and Assays
  
• Lonza Inks Deal with Odyssey Thera Expanding Drug-Discovery and Safety-Testing Offerings
  
• Femta Signs On Lonza to Manufacture Preclinical RA Candidate
  
• Virdante Taps ProBioGen for Cell-Line Development
  
• Lonza and CSC to Provide hPSC-Derived Cells and Media for Research Community
  
• Lonza Negotiates License to Axxam’s Photoproteins for Clonetics Primary Sensor Cells
  
• Lonza to Manufacture HGS and GSK’s Lupus Drug Benlysta
  
• Lonza and Roslin Cells to Develop Media and Production Processes for Stem Cells
  
• Lonza Acquires Vivante to Expand into Viral-Based GMP Manufacturing
  
• Daiichi Sankyo Selects Kinaxo for Cancer Drug Development Collaboration
  
• ArQule and Daiichi Sankyo Broaden and Extend Oncology Partnership
  
• BD Diagnostics and Lonza to Market MicroCompass Molecular Assays for BD Max System
  
• ATMI Buys Partner Artelis to Acquire Disposable Bioreactor Platform and Expertise
  
• Dalton and Lonza Ink Contract Chemistry and Manufacturing Agreement
  
• Agensys Taps BioWa Technology for Cancer Antibody Discovery
  
• Lonza and CPRI Ally on Peptide Manufacturing and Development Services
  
• Omeros Adds Addiction and Compulsive Disorders to License Agreement with Daiichi
  
• Oxford BioTherapeutics Licenses BioWa Platform to Develop Antibody Therapeutics